IGC Pharma, Inc.

IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears

IGC Pharma received Canadian Patent No. 3,095,729 covering the composition of IGC-AD1, its investigational oral therapy for agitation in Alzheimer's. With this grant, IGC-AD1 is now patented in all three North American markets and protected by 5 granted patents, with 10 applications pending worldwide. The more significant near-term catalyst is the CALMA Phase 2 trial, which completed enrollment in September 2026 and is in its final dosing period, with topline results to follow database lock and unblinding. CEO Ram Mukunda framed the patent portfolio as support for long-term commercial value and a way to attract major pharmaceutical partners.

•4d ago

IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment

IGC Pharma introduced PRISM, a new application layer built on its patent-pending MINT-AD Alzheimer's AI platform, aimed at risk stratification, cognitive monitoring, and clinical trial optimization. The company says it is evaluating B2B, B2B2C, and direct-to-consumer commercialization pathways, but no contracts, licensing deals, or revenue commitments have been announced. PRISM complements the lead drug candidate IGC-AD1, now fully enrolled in the Phase 2 CALMA trial with 168 participants and topline results expected in Q4 2026.

•27d ago

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026

IGC Pharma completed enrollment in its Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer's dementia, with 168 participants randomized including planned over-enrollment. Final participant dosing is expected in early November, with topline results targeted for Q4 2026 after database lock and unblinding. The Data Safety Monitoring Committee has recommended the trial continue without modification at each periodic review, with no treatment-related serious adverse events identified to date. The primary endpoint is change in agitation from baseline to week six on the Cohen-Mansfield Agitation Inventory, tested across clinical sites in the United States and Canada.

•1mo ago

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

IGC Pharma announced its Phase 2 CALMA trial of IGC-AD1 is within six randomizations of enrollment closure, with topline data anticipated in Q4 2026. Q2 2026 financial results showed revenue of approximately $265,000 and a net loss of $3.0 million, or $0.03 per share. Cash and equivalents were approximately $331,000, supported by a $12 million credit facility with no outstanding debt. Management converted approximately $1.15 million of debt into 4.27 million shares of common stock at $0.27 per share to reduce obligations and preserve cash.

•2mo ago

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

IGC Pharma is preparing for the Phase 2 topline readout of its lead asset IGC-AD1 in the fourth quarter of 2026, having randomized 160 participants in the CALMA trial to date. The company expects to close enrollment after up to eight additional randomizations and has engaged OPIS Research to assist with EMA regulatory interactions. The CALMA trial evaluates IGC-AD1 for agitation associated with Alzheimer's dementia, representing a significant upcoming clinical milestone for the firm.

•2mo ago

New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results

BioVie is scheduled to appear on the 'New to The Street' program on Bloomberg Television to discuss its recently reported Phase 2 SUNRISE-PD clinical results for bezisterim in early Parkinson's disease. The company previously reported that bezisterim showed statistically significant improvements in motor and non-motor symptoms compared to placebo, along with encouraging biomarker findings. The broadcast is sponsored programming airing at 6:30 PM ET, with international distribution across Latin America and MENA regions.

•3mo ago

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

IGC Pharma is evaluating potential civil remedies to recover damages following the federal jury verdict against Andrew Left of Citron Research regarding a 2018 short campaign. The federal indictment alleged the scheme generated over $3.8 million in profits for a hedge fund and over $1.1 million for Left, while a separate SEC proceeding noted Anson Advisors generated $500,000 in profits from a bearish tweet. CEO Ram Mukunda stated the company is reviewing the public record to determine recoverable damages for harm to market value and reputation, though operations remain focused on the Phase 2 CALMA trial for IGC-AD1.

•3mo ago

New to The Street(R) to Broadcast Show #762 Tonight on Bloomberg Television at 6:30 PM ET, Featuring Envoy Medical (NASDAQ:COCH), AlphaCompute (NASDAQ:ALP), RHINO Bitcoin (OTC PINK:RHNO), and Big Sky Industrial (NASDAQ:BSIN)

AlphaCompute is scheduled to appear on New to The Street Show #762 airing tonight at 6:30 p.m. ET on Bloomberg Television. The segment will showcase the company's next-generation artificial intelligence infrastructure and high-performance computing solutions. The broadcast will reach audiences in the U.S., MENA, and Latin America, alongside features on Envoy Medical, RHINO Bitcoin, and Big Sky Industrial.

•3mo ago

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow

IGC Pharma will present seven scientific posters at the AAIC 2026 conference in London, showcasing its AI portfolio for Alzheimer's drug discovery. The centerpiece is the AHA platform, which reduced data harmonization time by 90% (from 28 to 2.5 hours) in a representative internal workflow involving 100 variables. Separately, the company confirmed its lead asset IGC-AD1 has reached 100% of its baseline randomization target in the Phase 2 CALMA trial, with limited over-enrollment currently underway.

•4mo ago

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

IGC Pharma CEO Ram Mukunda and CFO Claudia Grimaldi purchased an aggregate of 4.27 million shares of common stock at $0.27 per share by cancelling approximately $1.15 million in debt owed to them by the company. The transaction includes over $552,000 in personal cash previously advanced to the company by the executives and eliminates outstanding obligations without any cash payment by IGC. The issuance of restricted common stock was approved by independent directors and priced at market value, which management stated aligns their interests directly with shareholders.

•4mo ago

IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow

IGC Pharma announced the beta release of its Agentic Harmonization Assistant (AHA), a multi-agent AI platform designed to accelerate the harmonization of fragmented Alzheimer's datasets. Internal testing demonstrated a 90% reduction in workflow time, reducing a manual process taking 28 hours down to 2.5 hours for a representative workflow involving 100 variables. Separately, the company confirmed that its Phase 2 CALMA trial for lead asset IGC-AD1 has reached 100% of its baseline randomization target.

•4mo ago

IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

IGC Pharma added the Icahn School of Medicine at Mount Sinai as a clinical site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's disease. The trial is approximately 80% complete in terms of participant enrollment, with the company now focused on database lock and topline analysis. CEO Ram Mukunda stated that adding world-class sites like Mount Sinai supports final-stage execution, patient access, and data integrity as the program advances.

•5mo ago